MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

36.05 -0.83

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.92

Max

36.49

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	12.073 90.831
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+20.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	517M 2.2B
Eelmine avamishind	36.88
Eelmine sulgemishind	36.05

Uudiste sentiment

By Acuity

50%

159 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. jaan 2026, 23:29 UTC

Kuumad aktsiad

Stocks to Watch: Atossa Therapeutics, Union Pacific

17. jaan 2026, 15:06 UTC

Omandamised, ülevõtmised, äriostud

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17. jaan 2026, 10:30 UTC

Tulu

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

17. jaan 2026, 03:10 UTC

Omandamised, ülevõtmised, äriostud

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16. jaan 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. jaan 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 21:48 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. jaan 2026, 21:41 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. jaan 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. jaan 2026, 20:44 UTC

Tulu

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. jaan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. jaan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. jaan 2026, 19:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16. jaan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16. jaan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16. jaan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

20.16% tõus

12 kuu keskmine prognoos

Keskmine 43.75 USD 20.16%

Kõrge 55 USD

Madal 32 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

159 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.